|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 153.80 SEK | +0.92% |
|
-2.16% | -29.29% |
| 12-08 | CellaVision's Bone Marrow Aspirate Software Secures In Vitro Diagnostic Regulation Class C Classification | MT |
| 12-08 | Cellavision Secures CE Marking for Bone Marrow Application | FW |
| Capitalization | 3.67B 396M 337M 315M 295M 546M 35.75B 595M 1.43B 16.89B 1.49B 1.46B 61.54B | P/E ratio 2025 * |
23.8x | P/E ratio 2026 * | 20.2x |
|---|---|---|---|---|---|
| Enterprise value | 3.51B 379M 322M 301M 282M 522M 34.16B 568M 1.36B 16.14B 1.42B 1.39B 58.8B | EV / Sales 2025 * |
4.64x | EV / Sales 2026 * | 4.11x |
| Free-Float |
82.65% | Yield 2025 * |
1.73% | Yield 2026 * | 1.93% |
Last Transcript: CellaVision AB
| 1 day | +0.92% | ||
| 1 week | -2.16% | ||
| Current month | -6.67% | ||
| 1 month | -4.23% | ||
| 3 months | -15.40% | ||
| 6 months | -22.79% | ||
| Current year | -29.29% |
| 1 week | 150 |  | 159.8 |
| 1 month | 150 | | 167.4 |
| Current year | 147.8 | | 232.5 |
| 1 year | 147.8 | | 232.5 |
| 3 years | 120 | | 302 |
| 5 years | 120 | | 503.5 |
| 10 years | 44.7 | | 503.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Simon Ostergaard
CEO | Chief Executive Officer | 54 | 20/03/2021 |
Monica Jonsson
DFI | Director of Finance/CFO | 45 | 01/09/2025 |
Urban Strindlöv
SAM | Sales & Marketing | 61 | 31/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | - | |
Stefan Wolf
BRD | Director/Board Member | 61 | 03/05/2018 |
Mikael Worning
CHM | Chairman | 63 | 28/04/2021 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.92% | -2.16% | -31.95% | -34.69% | 396M | |
| -1.98% | -4.00% | +7.44% | -29.59% | 17.88B | |
| +0.03% | +5.72% | +78.23% | +256.74% | 2.6B | |
| +3.00% | +6.61% | -28.56% | -67.87% | 2.01B | |
| -0.65% | -0.97% | -1.86% | -8.12% | 1.13B | |
| +1.34% | +1.62% | +3.32% | -24.96% | 909M | |
| -1.10% | -3.10% | -5.72% | -44.46% | 873M | |
| +2.04% | +3.44% | -16.97% | -43.62% | 705M | |
| -2.76% | -10.21% | +302.72% | - | 510M | |
| +0.51% | +1.91% | -24.13% | -41.55% | 490M | |
| Average | +0.38% | -0.88% | +28.25% | -4.24% | 2.75B | |
| Weighted average by Cap. | +0.64% | -2.46% | +14.28% | -4.92% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 755M 81.56M 69.39M 64.78M 60.78M 112M 7.36B 122M 293M 3.48B 306M 300M 12.66B | 841M 90.88M 77.32M 72.19M 67.73M 125M 8.2B 136M 327M 3.87B 341M 334M 14.11B |
| Net income | 154M 16.64M 14.16M 13.22M 12.4M 22.93M 1.5B 24.96M 59.83M 709M 62.44M 61.12M 2.58B | 181M 19.61M 16.68M 15.58M 14.61M 27.02M 1.77B 29.42M 70.51M 836M 73.59M 72.03M 3.04B |
| Net Debt | -163M -17.64M -15.01M -14.01M -13.15M -24.31M -1.59B -26.46M -63.43M -752M -66.2M -64.8M -2.74B | -214M -23.14M -19.69M -18.38M -17.24M -31.89M -2.09B -34.71M -83.21M -986M -86.84M -85M -3.59B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/12/25 | 153.80 kr | +0.92% | 6,941 |
| 10/12/25 | 152.40 kr | +0.26% | 17,295 |
| 09/12/25 | 152.00 kr | -0.13% | 10,347 |
| 08/12/25 | 152.20 kr | -2.56% | 24,488 |
| 05/12/25 | 156.20 kr | -0.64% | 43,500 |
Delayed Quote Nasdaq Stockholm, December 11, 2025 at 05:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CEVI Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition